How Much Is Ozempic? The Full Price Breakdown (2026)

What Is the Ozempic List Price?

The number that gets quoted in headlines is the list price, or wholesale acquisition cost (WAC): $998 per month. That is the sticker before any insurance, coupon, or savings program touches it — and the figure to anchor every other price in this guide against. Ozempic is made by Novo Nordisk and FDA-approved for type 2 diabetes, though it is widely prescribed off-label for weight loss.

One useful thing to know: the dose makes no difference to the price. Whether you are titrating up or holding at the max, you pay the same list price:

• 0.25 mg (starting dose, weeks 1-4): $998/month
• 0.5 mg (maintenance dose): $998/month
• 1 mg (escalated dose): $998/month
• 2 mg (maximum dose): $998/month

To put $998 in perspective: the identical drug runs about $59/month in Germany, $89/month in the UK, and $155/month in Canada. American patients pay roughly 10x the price of every other developed country — which is exactly why the savings strategies further down this page matter so much.

Don't hold out for a list-price cut. Novo Nordisk has announced no reductions for 2026, and while competitive pressure from Eli Lilly's Zepbound and incoming Medicare coverage could eventually move the number, your savings today come from how you buy — not from waiting on the manufacturer.

The Three Ozempic Prices You'll See (and Which One You Pay)

The single biggest source of confusion around how much Ozempic costs is that there isn't one price — there are three, and which one applies to you depends entirely on your coverage. Novo Nordisk publishes a wholesale acquisition cost (WAC) of $935.77per monthly pen, the manufacturer's formal 2026 list price. Almost nobody pays exactly that, but every other figure is derived from it.

Here is how the three break down. The list price ($935.77) is what pharmacies pay before rebates and is mostly a reference point. The cash price is what an uninsured person hands over at the counter — usually within a few dollars of list. The insurance priceis the copay or coinsurance your plan's pharmacy benefit manager negotiates, and for commercially insured patients it typically lands somewhere between $25 and $200 a month. Knowing which bucket you fall into tells you your real number instantly.

One lever can pull a commercial copay all the way down: Novo Nordisk's NovoCare savings card can cap eligible commercially insured patients at as little as $25/monthfor up to 24 months. It won't help with Medicare, Medicaid, or TRICARE, and it does nothing for the cash price if you're uninsured — but for the right plan it's free money. Sign up at NovoCare.com with a valid prescription.

Ozempic Cost Without Insurance: What You Actually Pay

This is the scenario that scares people, and fairly so. Pay cash for brand-name Ozempic with no discount program and you're looking at roughly $890–$950 per monthat U.S. pharmacies in 2026 — essentially Novo's $935.77 list price, with Costco usually shaving off the most. Over a year that's more than $10,000 out of pocket.

The good news: almost nobody who knows the alternatives actually pays that. Without insurance, the cheaper routes are Oral Wegovy at $149/month direct from Novo Nordisk, Zepbound via LillyDirect at $349/month, telehealth self-pay programs that bundle the consult and medication starting around $199/month, and compounded semaglutide at roughly $200–$400/month (with growing FDA enforcement — see that section below). And if your income is under $62,400/year as an individual, NovoCare Patient Assistance can drop your cost to zero. The cash sticker is the worst-case number, not your only option.

Ozempic Price With Insurance

With coverage, your monthly Ozempic price is decided by three things: your plan type, where Ozempic sits on the formulary, and whether you've cleared your deductible yet. Those variables explain why two insured people can pay wildly different amounts. Here's what each situation typically costs:

The coverage trap to avoid:Ozempic is FDA-approved only for type 2 diabetes, so a weight-loss prescription can get denied outright — leaving you facing the full $998. If that's you, the cheaper move is to ask your doctor about Wegovy (the same semaglutide, but approved for weight loss) or Zepbound, both of which insurers cover far more readily for obesity. Switching the script can be the difference between a $25 copay and the full cash price.

Self-Pay Routes That Beat the Cash Price

No insurance, or a plan that won't touch Ozempic? You're not stuck at $998. Each of the four routes below knocks the monthly price down — some by a little, some by hundreds of dollars. Match yours to your situation:

Compounded Semaglutide: The Cheapest Price, With a Catch

On price alone, compounded semaglutide has been the headline-grabber — telehealth providers and compounding pharmacies list it at $149-$499/month, a fraction of brand Ozempic. But the cost math comes with a regulatory asterisk that shifted hard in 2025-2026:

• The FDA declared the semaglutide shortage officially over in early 2025, removing the legal basis for 503A compounding under the shortage exemption.
• The FDA has issued warning letters to 50+ compounding pharmacies and filed enforcement actions against several large compounders.
• Some 503B outsourcing facilities continue to compound semaglutide under different legal arguments, but their long-term legality remains uncertain.

The price-smart takeaway: compounded semaglutide may still show the lowest number, but the legal ground under it is shrinking — so factor in the risk of your supply disappearing mid-treatment. The encouraging part is that FDA-approved options have caught up on price: Oral Wegovy at $149/month and Zepbound via LillyDirect at $349/month now rival the compounded rate without the uncertainty. Read our full compounded vs brand comparison.

How Medicare Changes Your Ozempic Price in July 2026

For older patients, the price story is about to change in a big way. From July 1, 2026, Medicare begins covering GLP-1 medications for weight loss — a shift that brings an estimated 7.4 million beneficiaries with obesity (BMI 30+) or weight-related conditions (BMI 27+) into a copay that's a fraction of today's cash price.

Under the bridge program:

• Covered medications include Wegovy (semaglutide) and Zepbound (tirzepatide)
• Ozempic itself is covered for diabetes patients, not directly for weight loss under this program
• Estimated copay: $35-$50/month under most Part D plans
• Prior authorization will likely be required, including BMI documentation and failed lifestyle intervention

If you are 65+ and currently paying cash for Ozempic, the Medicare bridge program could cut your monthly cost by more than 90% once it lands. Ask your Part D plan about the formulary updates due in Q2 2026 so you're ready the day coverage opens. Read our full Medicare GLP-1 coverage guide.

Cheaper GLP-1 Alternatives to Ozempic

Sometimes the fastest way to lower your Ozempic price is to not buy Ozempic. Several other GLP-1 medications cost less per month — or are far easier to get covered — for the same or better results. Here is how the prices stack up:

• Wegovy ($1,349/month list): Same drug as Ozempic but FDA-approved for weight loss. Higher dose (2.4mg vs 2mg max). Better insurance coverage for obesity treatment. See Wegovy pricing.
• Zepbound ($1,059/month list, $349 self-pay): Tirzepatide targets both GLP-1 and GIP receptors. Clinical trials show 22.5% average weight loss vs 15% for semaglutide. LillyDirect makes it cheaper than Ozempic for self-pay patients. See Zepbound pricing.
• Mounjaro ($1,023/month list): Same drug as Zepbound but approved for diabetes. If you have type 2 diabetes, Mounjaro may have better insurance coverage than Ozempic. See Mounjaro pricing.
• Rybelsus ($936/month list): Oral semaglutide tablet for diabetes. Lower efficacy than injectable Ozempic at currently approved doses. Does not require injections. See Rybelsus pricing.